HIV 1 News and Research

RSS

New technology reveals cellular gene transcription process in detail

A new technology that reveals cellular gene transcription in greater detail has been developed by Dr. Daniel Kaufmann of the University of Montreal Hospital Research Centre and the research team he directed. "This new research tool offers us a more profound view of the immune responses that are involved in a range of diseases, such as HIV infection. At the level of gene transcription, this had been difficult, complex and costly to do with current technologies, such as microscopy," explained the University of Montreal professor.

4 Dec 2014

Study reports effective treatment approach to inhibit herpes virus infection

A multi-institutional study reports an effective treatment approach to inhibit and keep latent viruses like herpes simplex from reactivating and causing disease. The work, whose lead author is the late James Hill, PhD, LSU Health New Orleans Professor and Director of Pharmacology and Infectious Disease at the LSU Eye Center, is published in the December 3, 2014, issue of Science Translational Medicine.

4 Dec 2014

Joint therapy to counter HIV and HCV increases chance of success

A Spanish researcher has collaborated on a mathematical analysis, recently published in the journal 'Science Translational Medicine', which concludes that joint therapy to counter HIV in patients who also have hepatitis C increases the chance of success in the fight against both infections. Between eight and nine million people worldwide simultaneously suffer from AIDS and hepatitis C.

3 Dec 2014

UCLA researchers devise plan to reduce HIV transmission in Africa

While Ebola has attracted much of the world's attention recently, a severe HIV epidemic rages on around the world and in sub-Saharan Africa in particular. Globally, more than 34 million people are infected with HIV; in sub-Saharan Africa alone, 3 million new infections occur annually.

3 Dec 2014

InnaVirVax receives DSMB recommendation to pursue VAC-3S Phase 2 study in HIV

InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, today announces the recommendation of its independent Data Safety and Monitoring Board (DSMB) to pursue the Phase 2 study (IPROTECT1) of VAC-3S according to the planned protocol.

2 Dec 2014

HIV's ability to cause AIDS is declining, finds new research

The rapid evolution of HIV, which has allowed the virus to develop resistance to patients' natural immunity, is at the same time slowing the virus's ability to cause AIDS, according to new research funded by the Wellcome Trust.

2 Dec 2014

New cellPACK software can help explore human cells in more detail

Researchers can now explore viruses, bacteria and components of the human body in more detail than ever before with software developed at The Scripps Research Institute.

2 Dec 2014

(RED) raises money for ‘Global Fund to fight AIDS, Tuberculosis and Malaria’

As the world reaches a tipping point in the AIDS fight, (RED) and its iconic partners Apple, Bank of America, The Coca-Cola Company and Starbucks marked World AIDS Day 2014 by rallying millions of people around the AIDS fight, and raising money for the Global Fund to fight AIDS, TB and Malaria.

2 Dec 2014

Researchers develop low-cost, electricity-free device for detecting DNA of infectious pathogens

Diagnosing HIV and other infectious diseases presents unique challenges in remote locations that lack electric power, refrigeration, and appropriately trained health care staff. To address these issues, researchers funded by the National Institutes of Health have developed a low-cost, electricity-free device capable of detecting the DNA of infectious pathogens, including HIV-1.

2 Dec 2014

Mylan, CAS to raise funds and awareness for people living with HIV/AIDS

Mylan Inc. and the Canadian AIDS Society (CAS) today announced a joint initiative to raise funds and awareness for Canadians and people worldwide who are living with or at risk of HIV/AIDS.

2 Dec 2014

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF) as both a single agent product and in combination with other drugs.

1 Dec 2014

CCR5 receptor plays key role in driving prostate cancer metastases

Although prostate cancer can be successfully treated in many men, when the disease metastasizes to the bone, it is eventually lethal. In a study published online December 1st in the journal Cancer Research, researchers show that the receptor CCR5 best known for its role in HIV therapy, may also be involved in driving the spread of prostate cancer to the bone.

1 Dec 2014

Health Canada warns Canadians against illegal health products

A vendor in Atlantic Canada (www.health-recovery-info.com) is selling Miracle Mineral Solution (MMS), an unauthorized drug product which Health Canada has previously warned may pose serious risks to health if ingested.

29 Nov 2014

Health Canada updates Canadians regarding sale of unlicensed HIV test kits via Amazon.ca.

Health Canada is informing Canadians that multiple distributors (Positive Health, dailySupply, BestDealCA, eshopic, Urban Inspirations, grabthesale, and dealkings) are selling the unlicensed "OraQuick in Home HIV Test" kit via Amazon.ca.

29 Nov 2014

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics ("iCo" or "the Company"), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Nov 2014

Ansell launches #UniteToFightHIV campaign to raise awareness for World AIDS Day

Ansell, a global leader in protection solutions and the makers of LifeStyles Condoms, one of the nation's leading condom brands, today announced the launch of the #UniteToFightHIV, a social media campaign in partnership with the AIDS Healthcare Foundation to raise awareness for World AIDS Day on December 1, 2014.

29 Nov 2014

HIV drugs could be harnessed to treat leading cause of blindness

An established class of drugs, traditionally used to control HIV/AIDS infections, could soon be harnessed to treat the leading cause of blindness and visual impairment in the UK, for which currently there exists no cure.

27 Nov 2014

BWH researchers identify two-faced role of TIM-3 protein

A Brigham and Women's Hospital-led team has identified a long sought-after partner for a key immune protein, called TIM-3, that helps explain its two-faced role in the immune system -- sometimes dampening it, other times stimulating it. This newly identified partner not only sheds light on the inner workings of the immune system in diseases such as HIV, autoimmunity, and cancer, but also provides a critical path toward the development of novel treatments that target TIM-3.

26 Nov 2014

New hybrid vehicle to improve delivery of DNA vaccines is under development

Described recently in the Proceedings of the National Academy of Sciences, the technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses.

26 Nov 2014

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

The University of Texas Medical Branch is part of a collaboration led by the Oak Crest Institute of Science that received a $20 million grant from the National Institutes of Health to develop a novel intravaginal ring capable of delivering powerful antiretroviral drugs to prevent the spread of sexually transmitted HIV in women. The total award to UTMB is approximately $2.5 million.

26 Nov 2014